Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09, Zacks reports. The firm had revenue of $26.90 million during the quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $1.79 on Friday. Zentalis Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $16.27. The stock has a market cap of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75. The stock’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $2.86.

Insider Activity at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka bought 60,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ZNTL has been the subject of several research analyst reports. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Finally, Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.